In this video in the 8 in 8 Series, Dr. Dwight Owen (Ohio State University) discussed advances in biomarker testing and neoadjuvant immunotherapy for resectable non-small cell lung cancer. The talk includes a look at the role of PD-L1 testing, peri-operative chemo-immunotherapy, and the importance of NGS testing for patients with actionable mutations.

Supported by AstraZeneca.

7 min.

In this 8 in 8 video, Dr. Jessica Donington provides an update on adjuvant and neoadjuvant clinical trials that have recently concluded or will be releasing data in the near future. She reviews patient populations, methodology, and implications of trial findings for the treatment of resectable lung cancer.


Jessica S. Donington, MD, MSCR
University of Chicago Medicine & Biological Sciences
Chicago, IL

Supported by AstraZeneca

11 min

In part two of the Robotic Thoracic Surgery webinar series, experts will discuss how a collaborative thoracic and pulmonary robotic approach is expanding thoracic oncology. Through increased lung cancer screening and incidental pulmonary nodule programs, the management of 8-10 mm pulmonary nodules in high-risk patients has come to the forefront, especially with the growing adoption of robotic navigational bronchoscopy and its associated greater precision. This webinar will explore best practices and current technology in the pulmonary and thoracic fields, as well as emerging therapies.

1 hr. 10 min.

In this panel discussion, STS members exchange viewpoints on a new study that found patients with postoperative PE had increased 30-day mortality, reintubation, and readmission rates, which was presented at the 2024 STS Annual Meeting.

10 min

As key members of the multidisciplinary care team, thoracic surgeons play a pivotal role in the patient journey for resectable Non-Small Cell Lung Cancer. This patient journey map, suitable for both surgeons and patients, outlines the stages of treatment of resectable NSCLC from diagnosis and staging, to resection, referral to a medical oncologist, and surveillance. This includes consideration of biomarker testing during the diagnostic biopsy and resection stages, and the potential benefit of perioperative and adjuvant therapies.

Click the image below to view or download the full document.

Patient Journey Resectable NSCLC




Additional Resources




Mar 8, 2024
1 min read

In this video, Dr. Leah Backhus, thoracic surgeon and professor of cardiothoracic surgery at Stanford Medicine, discusses the surgeon’s role in managing patients with resectable non-small cell lung cancer.

12 min. 44 sec.
New research presented at STS 2024 found that patients with postoperative PE had increased 30-day mortality, reintubation, and readmission rates.
Feb 14, 2024

Impact of Surgical Factors on Event-Free Survival in the Randomized, Placebo-Controlled, Phase 3 KEYNOTE-671 Trial of Perioperative Pembrolizumab For Early Stage Non-Small-Cell Lung Cancer

In a talk given by presenting author Jonathan David Spicer, MD, PhD, of McGill University, he discussed new findings from the KEYNOTE-671 research study, focused on resectable early stage non-small-cell lung cancer (NSCLC), which have unveiled a significant breakthrough in the treatment landscape. 

The study, titled "Impact of Surgical-Related Data on Event-Free Survival in KEYNOTE-671," demonstrated that neoadjuvant therapy with pembrolizumab plus chemotherapy did not delay surgery. "Results showed that neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab provided meaningful improvement in EFS," said Dr. Spicer. "This was shown when compared with neoadjuvant chemotherapy alone for resectable early stage NSCLC – regardless of clinical nodal status, baseline disease stage, or type of surgery."

Longitudinal Follow-up of Elderly Patients After Esophageal Cancer Resection in the Society of Thoracic Surgeons General Thoracic Surgery Database

In this study, Justin Blasberg, MD, of Yale School of Medicine, used the STS General Thoracic Surgery Database linked to the Centers for Medicare and Medicaid Services data to define characteristics associated with long-term survival following esophagectomy for cancer. The analysis included 4,798 patients from 207 STS sites who underwent esophagectomy between 2012-2019. "The researchers found that Medicare patients undergoing esophagectomy for cancer exhibit identifiable predictors for long-term survival and readmission," noted Dr. Blasberg. "The absence of pathologic T and N downstaging increases the risk for long-term mortality and readmission."

These findings suggest opportunities to enhance clinical practice and improve outcomes for Medicare patients undergoing esophagectomy for cancer. 

Jan 27, 2024
2 min read

The 2024 Lung Transplant Symposium: Surgical and Medical Insights for Transplant Assessment and Management, presented at the STS 2024 pre-conference convening on Friday, January 26. Approximately 100 surgeons, pulmonologists, anesthesiologists, and other transplant team members learned about best-practice approaches for surgical and medical care of lung transplant patients – from assessment as candidates though post-surgical care as recipients.

"2024 Lung Symposium"
Nearly 100 surgeons, pulmonologists, anesthesiologists, and other transplant team members attended the 2024 Lung Transplant Symposium. 

After a welcome and introduction by STS President Dr. Tom MacGillivray, Dr. Shaf Keshavjee of the Toronto Lung Transplant Program at the University Health Network, gave a brief overview of lung transplantation firsts and milestones before moving into present-day breakthroughs and areas of concern. 
"Current noteworthy topics we’re addressing in lung transplantation include primary graft dysfunction, donor management, and organ repair centers, refining the transplant ecosystem, as well as understanding the challenges of retrieval and transport of organs," said Dr. Keshavjeee.

Five 90-minute sessions covered the following subject areas: recipient selection, donor selection, intraoperative management, postoperative management, and challenging situations led by expert panels who answered questions from attendees.

Among the wide range of presentations, the Symposium featured included, "ECMO as Bridge to Transplant;" "Organ Procurement Techniques -- DBD, DCD, or NRP;" "Perioperative and Intraoperative Anesthesia Management;" and "Diagnosis, Monitoring and Therapeutic Challenges," which each cited current research and case study results.

Jan 26, 2024
1 min read
ai and lung cancer screenings
Lung cancer is the deadliest cancer in the U.S. Early detection of lung cancer through low-dose computed tomography (LDCT) screening has been shown to significantly reduce lung cancer mortality in high-risk populations and is currently recommended annually by the U.S.
5 min read
Chi-Fu Jeffrey Yang, MD
lung preservation
While expanding geographic boundaries will ultimately enable better organ and recipient matching, it poses inherent challenges to organ preservation.
3 min read
Brandon A. Guenthart, MD
Discussion of two important clinical trials demonstrating equivalent survival for sublobar resection versus lobectomy for clinical stage IA.
46 min.